Suppr超能文献

交联肽纳米簇作为癌症疫苗传递肿瘤胚胎抗原。

Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine.

机构信息

School of Chemical & Biomolecular Engineering and Petit Institute for Bioengineering and Bioscience , Georgia Institute of Technology , Atlanta , Georgia 30332 , United States.

出版信息

Bioconjug Chem. 2018 Mar 21;29(3):776-785. doi: 10.1021/acs.bioconjchem.8b00079. Epub 2018 Feb 13.

Abstract

Peptide subunit vaccines are desirable because they increase control over the immune response and safety of the vaccine by reducing the risk of off-target responses to molecules other than the target antigen. The immunogenicity of most peptides, however, is low. Peptide nanoclusters (PNC) are proposed as a subunit peptide vaccine delivery system made completely of cross-linked peptide antigen that could improve the immunogenicity of a peptide vaccine. Proof of concept is demonstrated with oncofetal antigen (OFA), an immature laminin receptor protein expressed by many hematologic cancer cells but not by healthy cells. Peptide epitopes from this protein, called OFA 1, 2, and 3, were synthesized into PNC as a potential cancer peptide vaccine delivery system. PNC were formed by desolvation and stabilized with disulfide bonds using a trithiol cross-linker. Cysteines were added to the C-terminus of each peptide to assist in this cross-linking step, denoted OFA 1C, 2C, and 3C PNC. OFA 2C was found to form the smallest PNC, 148 ± 15 nm in diameter and stable in solution. This size is in the range where particles are readily internalized by dendritic cells (DCs) and may also passively diffuse to regional lymph nodes. OFA 2C PNC and soluble OFA 2C were internalized similarly by DCs in vitro, but only PNC resulted in significant peptide presentation by DCs. This indicates the potential for PNC to improve immune activation against this antigen. Additionally, PNC displayed higher retention at the intradermal injection site in vivo than soluble peptide, allowing more time to interact with DCs in an area of increased DC activity. While offering traditional nanoparticle benefits such as increased DC recognition, slower diffusion, and potential for multivalent cellular interactions, PNC also maximize antigen delivered per particle while minimizing off-target material delivery because the antigens are the main building blocks of the particle. With these properties, PNC are a delivery system with potential to increase peptide subunit vaccine immunogenicity for OFA and other peptide antigens.

摘要

肽亚单位疫苗是理想的,因为它们通过降低对靶抗原以外的分子的非靶向反应的风险,增加了对免疫反应和疫苗安全性的控制。然而,大多数肽的免疫原性较低。肽纳米团簇(PNC)被提议作为一种亚单位肽疫苗递送系统,完全由交联的肽抗原组成,这可能会提高肽疫苗的免疫原性。概念验证是用肿瘤胚胎抗原(OFA)进行的,OFA 是一种不成熟的层粘连蛋白受体蛋白,许多血液癌细胞表达,但健康细胞不表达。来自该蛋白的肽表位,称为 OFA1、2 和 3,被合成到 PNC 中作为一种潜在的癌症肽疫苗递送系统。PNC 通过去溶剂化形成,并使用三硫醇交联剂用二硫键稳定。在每个肽的 C 末端添加半胱氨酸以协助此交联步骤,分别表示为 OFA1C、2C 和 3C PNC。发现 OFA2C 形成最小的 PNC,直径为 148±15nm,在溶液中稳定。这个大小是颗粒容易被树突状细胞(DC)内化的范围,也可能被动扩散到区域淋巴结。OFA2C PNC 和可溶性 OFA2C 在体外被 DC 以相似的方式内化,但只有 PNC 导致 DC 显著呈递肽。这表明 PNC 有可能改善针对该抗原的免疫激活。此外,PNC 在体内皮内注射部位的保留时间长于可溶性肽,允许更多的时间与 DC 相互作用,增加 DC 活性区域。虽然提供了传统纳米颗粒的益处,如增加 DC 识别、减缓扩散和潜在的多价细胞相互作用,但 PNC 还最大限度地提高了每个颗粒递送的抗原量,同时最小化了非靶向材料的递送,因为抗原是颗粒的主要构建块。具有这些特性,PNC 是一种具有提高 OFA 和其他肽抗原的肽亚单位疫苗免疫原性潜力的递送系统。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验